Stock Events

Stock Events

ProPhase Labs 

$0.09
63
+$0+1.88% Today

Statistics

Day High
0.12
Day Low
0.08
52W High
6.7
52W Low
0.07
Volume
58,294
Avg. Volume
394,765
Mkt Cap
4.25M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jun 22
$3
Mar 22
$3
Jun 21
$3
Dec 19
$2.5
Jan 19
$2.5
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

1AprExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-1.86
-1.27
-0.67
-0.08
Expected EPS
-1.2
Actual EPS
N/A

Financials

-788.24%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
13.54MRevenue
-106.73MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PRPH. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson is a major competitor in the healthcare sector, offering a wide range of products that could compete with ProPhase Labs' offerings in diagnostics and health services.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories competes with ProPhase Labs in the diagnostics and medical devices sector, particularly in the development of tests and health monitoring devices.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical and biotechnology corporation that competes with ProPhase Labs in the research, development, and marketing of healthcare products.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a global healthcare company that competes with ProPhase Labs in the pharmaceuticals and health services market, including the development of treatments and diagnostics.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is a global biopharmaceutical company that competes with ProPhase Labs in the development and marketing of prescription medicines across several therapeutic areas.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. is a biopharmaceutical company that competes with ProPhase Labs in the development and marketing of antiviral drugs used in the treatment of infectious diseases.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. is a biopharmaceutical company that competes with ProPhase Labs in the discovery, development, and delivery of innovative human therapeutics.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie Inc. competes with ProPhase Labs in the biopharmaceutical field, focusing on developing and marketing advanced therapies for complex and serious diseases.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG is a global pioneer in pharmaceuticals and diagnostics that competes with ProPhase Labs in the diagnostics and personalized healthcare sectors.
Novartis
NVS
Mkt Cap237.61B
Novartis AG is a global healthcare company that competes with ProPhase Labs in developing and marketing a wide range of healthcare products, including innovative medicines and diagnostics.

About

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Show more...
CEO
Mr. Ted William Karkus
Employees
96
Country
US
ISIN
US74345W2070

Listings

OTC Link
US
PRPH

0 Comments

Share your thoughts

FAQ

What is ProPhase Labs stock price today?▼
The current price of PRPH is $0.09 USD — it has increased by +1.88% in the past 24 hours. Watch ProPhase Labs stock price performance more closely on the chart.
What is ProPhase Labs stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange ProPhase Labs stocks are traded under the ticker PRPH.
Is ProPhase Labs stock price growing?▼
PRPH stock has risen by +23.84% compared to the previous week, the month change is a -33.95% fall, over the last year ProPhase Labs has showed a -97.55% decrease.
What is ProPhase Labs market cap?▼
Today ProPhase Labs has the market capitalization of 4.25M
What is ProPhase Labs revenue for the last year?▼
ProPhase Labs revenue for the last year amounts to 13.54M USD.
What is ProPhase Labs net income for the last year?▼
PRPH net income for the last year is -106.73M USD.
Does ProPhase Labs pay dividends?▼
Yes, PRPH dividends are paid annual. The last dividend per share was 3 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does ProPhase Labs have?▼
As of April 01, 2026, the company has 96 employees.
In which sector is ProPhase Labs located?▼
ProPhase Labs operates in the Health Care sector.
When did ProPhase Labs complete a stock split?▼
The last stock split for ProPhase Labs was on December 22, 2025 with a ratio of 1:10.
Where is ProPhase Labs headquartered?▼
ProPhase Labs is headquartered in Garden City, US.